Kailera Therapeutics, a Nasdaq‑listed Waltham firm, traces its weight‑loss pipeline back to Shanghai’s Hengrui Pharma, China’s top‑valued drugmaker. The joint venture, backed by Bain Capital Life Sciences, raised $719 million in its IPO, positioning it among the largest U.S. biotech listings ever.

The NewCo model lets U.S. investors tap early‑stage Chinese assets while sidestepping FDA hurdles on Chinese trials. Hengrui holds nearly 10% of Kailera and sits on its board, ensuring continued collaboration. Analysts note that U.S. early‑stage testing shares fell to 35% from 48% in 2015, as China now accounts for 40% of global pre‑clinical work.

For investors, the trend signals a shift toward cross‑border biotech incubators that can fast‑track promising compounds into the world’s biggest market. The structure also dilutes regulatory risk for Chinese firms, who gain equity upside instead of full cash payouts. Ultimately, U.S. investors stand to profit from a pipeline that blends rapid Chinese development with American commercialization.